Terms: = Astrocytoma AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Diagnosis
184 results:
1. A syngeneic spontaneous zebrafish model of
Weiss A; D'Amata C; Pearson BJ; Hayes MN
Elife; 2024 Jul; 13():. PubMed ID: 39052000
[TBL] [Abstract] [Full Text] [Related]
2. Clinical and molecular features of patients with IDH1 wild-type primary glioblastoma presenting unexpected short-term survival after gross total resection.
Toyoda M; Shibahara I; Shigeeda R; Fujitani K; Tanihata Y; Hyakutake Y; Handa H; Komai H; Sato S; Inukai M; Hide T; Shimoda Y; Kanamori M; Endo H; Saito R; Matsuda KI; Sonoda Y; Kumabe T
J Neurooncol; 2024 Aug; 169(1):39-50. PubMed ID: 38839702
[TBL] [Abstract] [Full Text] [Related]
3. Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma.
Repici A; Ardizzone A; De Luca F; Colarossi L; Prestifilippo A; Pizzino G; Paterniti I; Esposito E; Capra AP
Cells; 2024 Feb; 13(4):. PubMed ID: 38391974
[TBL] [Abstract] [Full Text] [Related]
4. Integrated Proteogenomics Uncover Mechanisms of Glioblastoma Evolution, Pointing to Novel Therapeutic Targets.
Li J; Shih LK; Brat DJ
Cancer Res; 2024 May; 84(9):1379-1381. PubMed ID: 38330148
[TBL] [Abstract] [Full Text] [Related]
5. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma.
Lim-Fat MJ; Iorgulescu JB; Rahman R; Bhave V; Muzikansky A; Woodward E; Whorral S; Allen M; Touat M; Li X; Xy G; Patel J; Gerstner ER; Kalpathy-Cramer J; Youssef G; Chukwueke U; McFaline-Figueroa JR; Nayak L; Lee EQ; Reardon DA; Beroukhim R; Huang RY; Bi WL; Ligon KL; Wen PY
Clin Cancer Res; 2024 Apr; 30(7):1327-1337. PubMed ID: 38252427
[TBL] [Abstract] [Full Text] [Related]
6. Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors.
On J; Natsumeda M; Takahashi H; Koyama A; Shibuma S; Shibata N; Watanabe J; Saito S; Kanemaru Y; Tsukamoto Y; Okada M; Ogura R; Eda T; Tada M; Shimizu H; Adachi JI; Mishima K; Nishikawa R; Kakita A; Oishi M
J Neurooncol; 2024 Jan; 166(2):273-282. PubMed ID: 38227143
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These Tumors Potential Candidates for Immune Checkpoint Blockade?
Mahajan S; Singh J; Dandapath I; Jha P; Chaturvedi S; Ahuja A; Bhardwaj M; Saran R; Garg A; Sharma MC; Manjunath N; Suri A; Sarkar C; Suri V
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):84-95. PubMed ID: 38158760
[TBL] [Abstract] [Full Text] [Related]
8. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
Hadad S; Gupta R; Oberheim Bush NA; Taylor JW; Villanueva-Meyer JE; Young JS; Wu J; Ravindranathan A; Zhang Y; Warrier G; McCoy L; Shai A; Pekmezci M; Perry A; Bollen AW; Phillips JJ; Braunstein SE; Raleigh DR; Theodosopoulos P; Aghi MK; Chang EF; Hervey-Jumper SL; Costello JF; de Groot J; Butowski NA; Clarke JL; Chang SM; Berger MS; Molinaro AM; Solomon DA
Acta Neuropathol; 2023 Dec; 147(1):3. PubMed ID: 38079020
[TBL] [Abstract] [Full Text] [Related]
9. Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience.
Molica C; Gili A; Nardelli C; Pierini T; Arniani S; Beacci D; Mavridou E; Mandarano M; Corinaldesi R; Metro G; Gorello P; Giovenali P; Cenci N; Castrioto C; Lupattelli M; Roila F; Mecucci C; La Starza R
Sci Rep; 2023 Nov; 13(1):20101. PubMed ID: 37973912
[TBL] [Abstract] [Full Text] [Related]
10. SEGA-like circumscribed astrocytoma in a non-NF1 patient, harboring molecular profile of GBM. A case report.
Yamada S; Tanikawa M; Matsushita Y; Fujinami R; Yamada H; Sakomi K; Sakata T; Inagaki H; Yokoo H; Ichimura K; Mase M
Neuropathology; 2024 Jun; 44(3):190-199. PubMed ID: 37919875
[TBL] [Abstract] [Full Text] [Related]
11. A case of glioblastoma harboring non-amplified epidermal growth factor receptor variant III: Critical molecular detection using RNA-based panel analysis.
Kirishima M; Akahane T; Takajo T; Higa N; Yonezawa H; Uchida H; Kamimura K; Hanaya R; Yoshimoto K; Higashi M; Yoshiura T; Tanimoto A
Pathol Res Pract; 2023 Aug; 248():154712. PubMed ID: 37499520
[TBL] [Abstract] [Full Text] [Related]
12. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
Benusiglio PR; Elder F; Touat M; Perrier A; Sanson M; Colas C; Guerrini-Rousseau L; Tran DT; Trabelsi N; Carpentier C; Marie Y; Adam C; Bernier M; Cazals-Hatem D; Mokhtari K; Tran S; Mathon B; Capelle L; Dhooge M; Idbaih A; Alentorn A; Houillier C; Dehais C; Hoang-Xuan K; Cuzzubbo S; Carpentier A; Duval A; Coulet F; Bielle F
JCO Precis Oncol; 2023 May; 7():e2200525. PubMed ID: 37262394
[TBL] [Abstract] [Full Text] [Related]
13. Signaling Pathways in the Relapse of Glioblastoma.
Orozco-Mera J; Peralta-Pizza F; Escobar-Vidarte O; Coll-Tello B; Ariza A
Oncology (Williston Park); 2023 Mar; 37(3):107-117. PubMed ID: 36961958
[TBL] [Abstract] [Full Text] [Related]
14. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with egfr L858R Mutation.
Hou Z; Wu H; Luo N; Li S; Zhang X; Dong S; Zhu D; Zhang H; Tao R
Oncologist; 2023 May; 28(5):449-452. PubMed ID: 36913260
[TBL] [Abstract] [Full Text] [Related]
15. Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.
Romo CG; Piotrowski AF; Campian JL; Diarte J; Rodriguez FJ; Bale TA; Dahiya S; Gutmann DH; Lucas CG; Prichett L; Mellinghoff I; Blakeley JO
Neuro Oncol; 2023 Aug; 25(8):1474-1486. PubMed ID: 36840626
[TBL] [Abstract] [Full Text] [Related]
16. Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma.
Zhang GT; Liu Q; Zuo FX; Liu HJ; Wang SQ; Yuan Q; Liu AS; Hu K; Meng XL; Wang WJ; Qian HP; Wan JH; Cai HQ
BMC Cancer; 2023 Jan; 23(1):104. PubMed ID: 36717819
[TBL] [Abstract] [Full Text] [Related]
17. Using egfr amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors.
Friedman JS; Jun T; Rashidipour O; Huang KL; Ellis E; Kadaba P; Belani P; Nael K; Tsankova NM; Sebra R; Hormigo A
Cancer Immunol Immunother; 2023 Jun; 72(6):1893-1901. PubMed ID: 36707424
[TBL] [Abstract] [Full Text] [Related]
18. Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series.
Kibe Y; Motomura K; Ohka F; Aoki K; Shimizu H; Yamaguchi J; Nishikawa T; Saito R
Sci Rep; 2023 Jan; 13(1):23. PubMed ID: 36646712
[TBL] [Abstract] [Full Text] [Related]
19. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
[TBL] [Abstract] [Full Text] [Related]
20. Identification of a novel peptide ligand for the cancer-specific receptor mutation egfrvIII using high-throughput sequencing of phage-selected peptides.
Mansour S; Adhya I; Lebleu C; Dumpati R; Rehan A; Chall S; Dai J; Errasti G; Delacroix T; Chakrabarti R
Sci Rep; 2022 Dec; 12(1):20725. PubMed ID: 36456600
[TBL] [Abstract] [Full Text] [Related]
[Next]
